Sign In

Anand Tharmaratnam

Chairman of the Board Novotech Health Holdings

Professional Background

Anand Tharmaratnam is an accomplished healthcare executive with an impressive 26-year career in the medical and pharmaceutical industries. He is a trained anaesthesiologist who qualified as a medical doctor from University College London in the UK, specializing in Anaesthesiology. After beginning his career in anaesthesia and critical care medicine with the UK National Health Service, Anand transitioned to the healthcare industry in 1997, where he has made substantial contributions to clinical development and operational excellence on a global scale.

Anand's extensive tenure at Quintiles, the world’s largest drug development services company, is particularly notable. His journey at Quintiles began in 1997, and over the next 23 years, he played a crucial role in various strategic expansions and advancements. In 2001, he took a significant step by spearheading the expansion of Quintiles into India, where he established the world’s first off-shore clinical development ECG laboratory located in Mumbai. This initiative not only showcased his leadership but also demonstrated his ability to tap into emerging markets, ultimately paving the way for the company’s growth in regions like Japan, Brazil, and Peru.

Between 2004 and 2016, Anand was at the helm of the Quintiles Contract Research Organization (CRO) business in Asia Pacific & Japan, where he successfully transformed the business into a billion-dollar-a-year enterprise. His vision and leadership were instrumental in propelling the sales from low double-digit millions to over a billion dollars annually. His remarkable contributions culminated in 2013 when he became a key contributor to Quintiles going public on the New York Stock Exchange (NYSE). Anand's impressive career reached another significant milestone in 2016 when he was chosen to be part of the global executive team that merged Quintiles with IMS Health to create the formidable IQVIA—a moment that reshaped the landscape of healthcare data and analytics.

After the merger, Anand continued to lead IQVIA’s operations across Asia Pacific from 2016 to 2020, coordinating efforts that helped expand the influence and capabilities of the combined entity in this vital region. In his current role, Anand runs AskDrT Limited, a healthcare investment and management advisory practice based in London, UK, where he utilizes his extensive industry knowledge to provide strategic guidance.

Apart from his work with AskDrT, Anand serves as a senior advisor for healthcare to TPG Capital Asia, where he lends his expertise to enhance the performance of TPG Capital's portfolio companies. His influence is widely recognized as he currently holds the position of Chairman of Novotech Health Holdings, the largest independent CRO in the Asia Pacific region. Under his leadership, Novotech has evolved from its original business foundation in Australia into a multi-billion dollar valued CRO, focusing on enabling biotechnology companies globally.

Anand’s insight into innovative healthcare practices positions him as a valuable asset to numerous global advisory boards of forward-thinking healthcare companies. He has previously offered his counsel to Saama Technologies, a leader in AI-driven intelligent clinical trials, and currently advises Holmusk—a powerhouse in data science and health technology that emphasizes behavioral sciences. He serves as a board observer at ObvioHealth, an advanced provider of decentralized clinical trials.

Beyond his core dedication to the healthcare sector, Anand is also an investor in the entertainment industry, showcasing his multifaceted interests. He embraces life outside of work by spending quality time with his three teenage sons and indulging in his passions for food, sport, and travel, highlighting his commitment to a well-rounded lifestyle.

Education and Achievements

Anand Tharmaratnam’s educational background strongly complements his extensive professional experience in the medical field. He studied MRCA, achieving Membership from the Royal College of Anaesthetists, demonstrating his commitment to excellence within his specialty. His foundational medical education was completed at the prestigious University College London, U. of London, where he earned his MBBS degree in Medicine, equipping him with a profound understanding of both clinical skills and patient care.

Anand’s formative years were spent developing a strong academic foundation at Sevenoaks School, where he completed his 0 and A levels before progressing to university. This strong educational background prepared him for the rigorous challenges he faced throughout his esteemed career.

Throughout his impressive career, Anand has achieved several significant milestones and accolades that reflect his expertise and contributions to the healthcare industry. His work in transforming Quintiles and IQVIA operationally and financially has left an indelible mark on how clinical development is approached today, influencing countless patients’ lives through improved healthcare solutions.

Anand’s contributions highlight the importance of leadership and innovation in healthcare, inspiring many professionals to pursue excellence in their respective fields.

Achievements

  • Led the establishment of the first off-shore clinical development ECG laboratory in Mumbai, enhancing Quintiles' global footprint.
  • Instrumental in boosting the Quintiles CRO business in Asia Pacific & Japan to significant billion-dollar yearly sales from modest beginnings.
  • Played a crucial role in Quintiles' public offering on the NYSE in 2013.
  • Contributed to the merger between Quintiles and IMS Health to create IQVIA, enhancing data analytics in healthcare.
  • Currently serves as Chairman of Novotech Health Holdings, overseeing its growth to a multi-billion dollar valued CRO in Asia Pacific.

Related Questions

How did Anand Tharmaratnam transition from anaesthesia and critical care medicine to a successful career in healthcare executive roles?
What strategies did Anand Tharmaratnam employ to achieve billion-dollar sales for the Quintiles CRO business in Asia Pacific and Japan?
What impact did Anand Tharmaratnam's leadership have on the merger of Quintiles and IMS Health to create IQVIA?
In what ways does Anand Tharmaratnam contribute to the advancements in clinical trials through his advisory roles?
How has Anand Tharmaratnam's background in anaesthesiology shaped his perspective in leadership within the healthcare industry?
A
Add to my network

Location

Kensington & Chelsea, England, United Kingdom